Limits...
Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.

Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, Kronqvist P - Br. J. Cancer (2008)

Bottom Line: Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI.In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity.The finding urges further prognostic studies with a large sample of patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Turku University Hospital, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland. kattal@utu.fi

ABSTRACT
We introduce a new proliferation marker, securin (pituitary tumour-transforming 1 (PTTG1)), analysed in invasive ductal breast carcinomas by cDNA microarrays and immunohistochemistry. In cDNA microarray of a total of 4000 probes of genes, securin was revealed with a significant change in expression among the several proliferation-related genes studied. The value of securin as a proliferation marker was verified immunohistochemically (n=44) in invasive ductal breast cancer. In follow-up analyses of the sample of patients, the prognostic value of securin was compared with the established markers of breast cancer proliferation, Ki-67 and mitotic activity index (MAI). Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI. In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity. We suggest that securin immunostaining is a promising and clinically applicable proliferation marker. The finding urges further prognostic studies with a large sample of patients.

Show MeSH

Related in: MedlinePlus

Securin immunohistochemistry in invasive ductal breast cancer. The bar represents 50 μm.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2480969&req=5

fig1: Securin immunohistochemistry in invasive ductal breast cancer. The bar represents 50 μm.

Mentions: cDNA microarray analysis revealed a total of 131 transcripts upregulated and 256 transcripts downregulated in our sample of invasive breast cancers, corresponding to 119 and 224 up- and downregulated genes, respectively. These represented several significantly deregulated gene groups encoding proteins participating in DNA replication, regulation of cell proliferation, protein biosynthesis, superoxide dismutase activity and cytokine production. We concentrated on proliferation-related genes, among which securin showed clear deregulation and the most promising clinical applications with a consistent immunohistochemical expression pattern (Figure 1).


Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.

Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, Kronqvist P - Br. J. Cancer (2008)

Securin immunohistochemistry in invasive ductal breast cancer. The bar represents 50 μm.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2480969&req=5

fig1: Securin immunohistochemistry in invasive ductal breast cancer. The bar represents 50 μm.
Mentions: cDNA microarray analysis revealed a total of 131 transcripts upregulated and 256 transcripts downregulated in our sample of invasive breast cancers, corresponding to 119 and 224 up- and downregulated genes, respectively. These represented several significantly deregulated gene groups encoding proteins participating in DNA replication, regulation of cell proliferation, protein biosynthesis, superoxide dismutase activity and cytokine production. We concentrated on proliferation-related genes, among which securin showed clear deregulation and the most promising clinical applications with a consistent immunohistochemical expression pattern (Figure 1).

Bottom Line: Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI.In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity.The finding urges further prognostic studies with a large sample of patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Turku University Hospital, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland. kattal@utu.fi

ABSTRACT
We introduce a new proliferation marker, securin (pituitary tumour-transforming 1 (PTTG1)), analysed in invasive ductal breast carcinomas by cDNA microarrays and immunohistochemistry. In cDNA microarray of a total of 4000 probes of genes, securin was revealed with a significant change in expression among the several proliferation-related genes studied. The value of securin as a proliferation marker was verified immunohistochemically (n=44) in invasive ductal breast cancer. In follow-up analyses of the sample of patients, the prognostic value of securin was compared with the established markers of breast cancer proliferation, Ki-67 and mitotic activity index (MAI). Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI. In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity. We suggest that securin immunostaining is a promising and clinically applicable proliferation marker. The finding urges further prognostic studies with a large sample of patients.

Show MeSH
Related in: MedlinePlus